School of Chemistry, Monash University, Clayton, 3800, Australia.
Department of Chemistry, The University of Texas at Austin, 105 East 24th Street A5300, Austin, TX 78712-1224, USA.
Future Med Chem. 2020 Nov;12(22):2035-2065. doi: 10.4155/fmc-2020-0225. Epub 2020 Nov 10.
As bacteria continue to develop resistance to our existing treatment options, antibiotic innovation remains overlooked. If current trends continue, then we could face the stark reality of a postantibiotic era, whereby routine bacterial infections could once again become deadly. In light of a warning signaled by the WHO, a number of new initiatives have been established in the hope of reinvigorating the antibiotic drug development pipeline. In this perspective, we aim to summarize some of these initiatives and funding options, as well as providing an insight into the predicament that we face. Using clinical trials data, company website information and the most recent press releases, a current update of the antibiotic drug development pipeline is also included.
随着细菌对现有治疗方法的耐药性不断增强，抗生素创新仍然被忽视。如果当前的趋势持续下去，我们可能会面临一个后抗生素时代的严峻现实，到那时，常规的细菌感染可能再次变得致命。鉴于世界卫生组织发出的警告信号，已经建立了一些新的举措，希望重振抗生素药物开发管道。在这个角度下，我们旨在总结其中的一些举措和资金选择，并深入探讨我们所面临的困境。我们使用临床试验数据、公司网站信息和最新的新闻稿，对抗生素药物开发管道进行了最新的更新。
